These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
404 related articles for article (PubMed ID: 1353504)
1. The effect of changing somatostatin tone on the pituitary growth hormone and thyroid-stimulating hormone responses to their respective releasing factor stimuli. Spoudeas HA; Matthews DR; Brook CG; Hindmarsh PC J Clin Endocrinol Metab; 1992 Aug; 75(2):453-8. PubMed ID: 1353504 [TBL] [Abstract][Full Text] [Related]
2. Impaired inhibitory effects of somatostatin on growth hormone (GH)-releasing hormone stimulation of GH secretion after short term infusion. Kelijman M; Frohman LA J Clin Endocrinol Metab; 1990 Jul; 71(1):157-63. PubMed ID: 1973420 [TBL] [Abstract][Full Text] [Related]
3. The role of the cholinergic pathway in growth hormone feedback. Kelijman M; Frohman LA J Clin Endocrinol Metab; 1991 May; 72(5):1081-7. PubMed ID: 1902484 [TBL] [Abstract][Full Text] [Related]
6. Effect of enhancement of endogenous cholinergic tone with pyridostigmine on the dose-response relationships of growth hormone (GH)-releasing hormone-induced GH secretion in normal subjects. Peñalva A; Muruais C; Casanueva FF; Dieguez C J Clin Endocrinol Metab; 1990 Feb; 70(2):324-7. PubMed ID: 2105328 [TBL] [Abstract][Full Text] [Related]
7. Cholinergic receptor activation by pyridostigmine restores growth hormone (GH) responsiveness to GH-releasing hormone administration in obese subjects: evidence for hypothalamic somatostatinergic participation in the blunted GH release of obesity. Cordido F; Casanueva FF; Dieguez C J Clin Endocrinol Metab; 1989 Feb; 68(2):290-3. PubMed ID: 2493023 [TBL] [Abstract][Full Text] [Related]
8. The decrease in growth hormone (GH) response after repeated stimulation with GH-releasing hormone is partly caused by an elevation of somatostatin tonus. Reichardt B; Schrader M; Mojto J; Mehltretter G; Müller OA; Schopohl J J Clin Endocrinol Metab; 1996 May; 81(5):1994-8. PubMed ID: 8626871 [TBL] [Abstract][Full Text] [Related]
9. Role of the serotonin receptor subtype 5-HT1D on basal and stimulated growth hormone secretion. Mota A; Bento A; Peñalva A; Pombo M; Dieguez C J Clin Endocrinol Metab; 1995 Jun; 80(6):1973-7. PubMed ID: 7775648 [TBL] [Abstract][Full Text] [Related]
10. Activation of cholinergic neurotransmission by pyridostigmine reverses the inhibitory effect of hyperglycemia on growth hormone (GH) releasing hormone-induced GH secretion in man: does acute hyperglycemia act through hypothalamic release of somatostatin? Peñalva A; Burguera B; Casabiell X; Tresguerres JA; Dieguez C; Casanueva FF Neuroendocrinology; 1989 May; 49(5):551-4. PubMed ID: 2566942 [TBL] [Abstract][Full Text] [Related]
11. Effect of central cholinergic neurotransmission enhancement by pyridostigmine on the growth hormone secretion elicited by clonidine, arginine, or hypoglycemia in normal and obese subjects. Cordido F; Dieguez C; Casanueva FF J Clin Endocrinol Metab; 1990 May; 70(5):1361-70. PubMed ID: 2159483 [TBL] [Abstract][Full Text] [Related]
12. Effect of pyridostigmine on the thyroid-stimulating hormone response to thyrotropin-releasing hormone in abstinent alcoholics. Coiro V; Vescovi PP Alcohol Clin Exp Res; 1997 Oct; 21(7):1308-11. PubMed ID: 9347094 [TBL] [Abstract][Full Text] [Related]
13. Studies of growth hormone secretion in calorically restricted dogs: effect of cholinergic agonists and antagonists, glucose and thyrotropin-releasing hormone. Arce VM; Cella SG; Locatelli V; Müller EE Neuroendocrinology; 1991 May; 53(5):467-72. PubMed ID: 1908062 [TBL] [Abstract][Full Text] [Related]
14. Cholinergic control of growth hormone (GH) responses to GH-releasing hormone in insulin dependent diabetics: evidence for attenuated hypothalamic somatostatinergic tone and decreased GH autofeedback. Ismail IS; Scanlon MF; Peters JR Clin Endocrinol (Oxf); 1993 Feb; 38(2):149-57. PubMed ID: 8094648 [TBL] [Abstract][Full Text] [Related]
15. Effects of a prolonged growth hormone (GH)-releasing peptide infusion on pulsatile GH secretion in normal men. Jaffe CA; Ho PJ; Demott-Friberg R; Bowers CY; Barkan AL J Clin Endocrinol Metab; 1993 Dec; 77(6):1641-7. PubMed ID: 7903313 [TBL] [Abstract][Full Text] [Related]
16. Interaction of the growth hormone releasing peptide hexarelin with somatostatin. Massoud AF; Hindmarsh PC; Brook CG Clin Endocrinol (Oxf); 1997 Nov; 47(5):537-47. PubMed ID: 9425393 [TBL] [Abstract][Full Text] [Related]
17. Melatonin stimulates growth hormone secretion through pathways other than the growth hormone-releasing hormone. Valcavi R; Zini M; Maestroni GJ; Conti A; Portioli I Clin Endocrinol (Oxf); 1993 Aug; 39(2):193-9. PubMed ID: 8370132 [TBL] [Abstract][Full Text] [Related]
18. Growth hormone responses to growth hormone-releasing hormone and hexarelin in fed and fasted dogs: effect of somatostatin infusion or pretreatment with pirenzepine. Rigamonti AE; Marazzi N; Cella SG; Cattaneo L; Müller EE J Endocrinol; 1998 Feb; 156(2):341-8. PubMed ID: 9518881 [TBL] [Abstract][Full Text] [Related]
19. Pyridostigmine blocks the inhibitory effect of glucocorticoids on growth hormone-releasing hormone stimulated growth hormone secretion in normal man. Giustina A; Girelli A; Doga M; Bodini C; Bossoni S; Romanelli G; Wehrenberg WB J Clin Endocrinol Metab; 1990 Sep; 71(3):580-4. PubMed ID: 2118535 [TBL] [Abstract][Full Text] [Related]
20. Repeated administration of growth hormone-releasing hormone with or without previous administration of pyridostigmine in insulin-dependent diabetes mellitus. Martina V; Bruno G; Tagliabue M; Maccario M; Bertaina S; Zumpano E; Arvat E; Ghigo E; Camanni F Horm Metab Res; 1997 Apr; 29(4):180-3. PubMed ID: 9178028 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]